PMID- 21621587
OWN - NLM
STAT- MEDLINE
DCOM- 20120508
LR  - 20181201
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 499
IP  - 1
DP  - 2011 Jul 15
TI  - The effects of mirtazapine and fluoxetine on hyperthermia induced by 
      3,4-methylenedioxymethamphetamine (MDMA) in rats.
PG  - 24-7
LID - 10.1016/j.neulet.2011.05.024 [doi]
AB  - The use of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") as a recreational 
      drug has spread worldwide. Fatal hyperthermia is a likely side effect of using 
      MDMA in combination with monoamine oxidase inhibitors. However, most 
      antidepressants do not pose a high risk of developing hyperthermia when used in 
      conjunction with MDMA. Mirtazapine is a novel antidepressant and a potent 
      5-HT(2A) receptor antagonist. It remains to be elucidated whether mirtazapine is 
      unlikely to have life-threatening implications in combination with MDMA. In the 
      present study, we evaluated whether mirtazapine and fluoxetine influence 
      MDMA-induced hyperthermia in rats. The rectal temperature of the rats increased 
      to above 41 degrees C following an injection of MDMA (10mg/kg). Pre- and post-treatment 
      administration of mirtazapine (5mg/kg) significantly attenuated MDMA-induced 
      hyperthermia. Administration of WAY100635 (1mg/kg), a 5-HT(1A) receptor 
      antagonist, did not influence the ability of mirtazapine to decrease hyperthermia 
      induced by MDMA. Although pretreatment administration of fluoxetine (10mg/kg) 
      significantly attenuated MDMA-induced hyperthermia, post-treatment administration 
      of the same drug had no effect. The differences in body temperature between the 
      groups post-treated mirtazapine and the groups post-treated fluoxetine may be due 
      to differing mechanisms of action of the two antidepressants. The present study 
      indicates that mirtazapine is unlikely to induce fatal hyperthermia when used 
      with MDMA, and it may be rather effective against MDMA-induced hyperthermia. 
      Considering our previous study demonstrating that potent 5-HT(2A) antagonists 
      completely inhibit MDMA-induced hyperthermia, the findings of the present study 
      suggest that mirtazapine inhibits MDMA-induced hyperthermia mainly by blocking 
      the activation of 5-HT(2A) receptors.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Kasai, Makiko
AU  - Kasai M
AD  - Department of Psychiatry, Jichi Medical University, Tochigi-Ken 329-0498, Japan.
FAU - Shioda, Katsutoshi
AU  - Shioda K
FAU - Nisijima, Koichi
AU  - Nisijima K
FAU - Yoshino, Tatsuki
AU  - Yoshino T
FAU - Iwamura, Tatsunori
AU  - Iwamura T
FAU - Kato, Satoshi
AU  - Kato S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20110520
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Serotonin 5-HT2 Receptor Antagonists)
RN  - 0 (Serotonin Agents)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 250PJI13LM (Mianserin)
RN  - A051Q2099Q (Mirtazapine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents, Tricyclic/pharmacology
MH  - Disease Models, Animal
MH  - Fever/chemically induced/*drug therapy
MH  - Fluoxetine/*pharmacology
MH  - Male
MH  - Mianserin/*analogs & derivatives/pharmacology
MH  - Mirtazapine
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Serotonin 5-HT2 Receptor Antagonists/*pharmacology
MH  - Serotonin Agents/*toxicity
EDAT- 2011/05/31 06:00
MHDA- 2012/05/09 06:00
CRDT- 2011/05/31 06:00
PHST- 2011/02/15 00:00 [received]
PHST- 2011/05/09 00:00 [revised]
PHST- 2011/05/13 00:00 [accepted]
PHST- 2011/05/31 06:00 [entrez]
PHST- 2011/05/31 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - S0304-3940(11)00638-0 [pii]
AID - 10.1016/j.neulet.2011.05.024 [doi]
PST - ppublish
SO  - Neurosci Lett. 2011 Jul 15;499(1):24-7. doi: 10.1016/j.neulet.2011.05.024. Epub 
      2011 May 20.